D Ross Camidge

Summary

Country: UK

Publications

  1. pmc The causes of dysphagia in carcinoma of the lung
    D R Camidge
    Department of Oncology, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    J R Soc Med 94:567-72. 2001
  2. pmc The epidemiology of self-poisoning in the UK
    D R Camidge
    Scottish Poisons Information Bureau, Royal Infirmary of Edinburgh, Edinburgh EH3 9YW, UK
    Br J Clin Pharmacol 56:613-9. 2003
  3. pmc Prognosis without treatment as a modifier in health economic assessments
    Ross Camidge
    Clinical Pharmacology Unit, Western General Hospital, Edinburgh EH4 2XU
    BMJ 330:1382-4. 2005
  4. pmc Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data
    D R Camidge
    Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
    Br J Cancer 95:649-52. 2006
  5. pmc The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes
    D Ross Camidge
    University of Edinburgh, Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
    Br J Clin Pharmacol 65:224-9. 2008
  6. pmc Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK
    D R Camidge
    University of Edinburgh, Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh, UK
    Br J Cancer 96:752-7. 2007
  7. ncbi request reprint Self-poisoning in the UK: epidemiology and toxidromes
    Ross Camidge
    Western General Hospital, Edinburgh
    Clin Med 3:111-4. 2003
  8. ncbi request reprint A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
  9. ncbi request reprint Dynamic and modern: bringing the ethics of phase I trials up to date
    D Ross Camidge
    J Clin Oncol 24:5178-9; author reply 5179-80. 2006
  10. ncbi request reprint Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
    D Ross Camidge
    Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045 0508, USA
    Expert Opin Biol Ther 8:1167-76. 2008

Collaborators

Detail Information

Publications10

  1. pmc The causes of dysphagia in carcinoma of the lung
    D R Camidge
    Department of Oncology, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    J R Soc Med 94:567-72. 2001
    ....
  2. pmc The epidemiology of self-poisoning in the UK
    D R Camidge
    Scottish Poisons Information Bureau, Royal Infirmary of Edinburgh, Edinburgh EH3 9YW, UK
    Br J Clin Pharmacol 56:613-9. 2003
    ..After establishing definitions for different self-poisoning categories we discuss the published data on self-poisoning as they relate to suicide, accidental self-poisoning and deliberate self-harm in the UK...
  3. pmc Prognosis without treatment as a modifier in health economic assessments
    Ross Camidge
    Clinical Pharmacology Unit, Western General Hospital, Edinburgh EH4 2XU
    BMJ 330:1382-4. 2005
  4. pmc Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data
    D R Camidge
    Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
    Br J Cancer 95:649-52. 2006
    ....
  5. pmc The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes
    D Ross Camidge
    University of Edinburgh, Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK
    Br J Clin Pharmacol 65:224-9. 2008
    ....
  6. pmc Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK
    D R Camidge
    University of Edinburgh, Edinburgh Cancer Centre, Western General Hospital, Crewe Road, Edinburgh, UK
    Br J Cancer 96:752-7. 2007
    ..Some of these accidents, particularly accidental poisonings, may contain hidden deliberate acts. Previous DSH or accidents are potential markers for those most at risk, in whom to target interventional techniques...
  7. ncbi request reprint Self-poisoning in the UK: epidemiology and toxidromes
    Ross Camidge
    Western General Hospital, Edinburgh
    Clin Med 3:111-4. 2003
  8. ncbi request reprint A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
    ..i.d.) on days 1-14 every 21 days. Further disease-directed studies are warranted, such as in malignancies in the treatment of which both capecitabine and inhibitors of angiogenesis have previously been benchmarked as being effective...
  9. ncbi request reprint Dynamic and modern: bringing the ethics of phase I trials up to date
    D Ross Camidge
    J Clin Oncol 24:5178-9; author reply 5179-80. 2006
  10. ncbi request reprint Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors
    D Ross Camidge
    Developmental Therapeutics and Thoracic Oncology Programs, Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045 0508, USA
    Expert Opin Biol Ther 8:1167-76. 2008
    ..Apomab is a pro-apoptotic anticancer agonist monoclonal antibody against Death receptor 5 (DR5)/TNF-related apoptosis inducing ligand-receptor 2 (TRAIL-R2)...